Akeega Approved for BRCA2-Mutated Prostate Cancer

By News Health
3 months Ago

(MedPage Today) — The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on Friday.
The once-daily, fixed…

Source link : https://www.medpagetoday.com/hematologyoncology/prostatecancer/119017

Author :

Publish date : 2025-12-15 19:12:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

CDC Studies Suggest Slumping Flu Shot Protection

Organ Donation Guidance From CMS Warns Against Coercion, Rushed Decision-Making

Med Student's Misogyny Goes Viral; Vitamin K PSA; Fibermaxxing: Yea or Nay?

MedPAC Members Express Concern Over Medicare Docs' Ability to Absorb Cost Increases

Higher Odds of Liver Fibrosis in Women With Cardiometabolic Risks

Exercise to Thwart 'Chemo Brain' Shows Promise in Randomized Trial